Veröffentlichungsdatum: 16 November 2020
Projektträger – zwischengeschaltetes Finanzinstitut
LABORATOIRES THEA SAS
The project will support the company's research and development (R&D) investments for the development of new molecules, formulations and innovative drug delivery systems for ophthalmic use.
EIB financing will accelerate the research, development and innovation (RDI) efforts conducted by the Promoter.
- Dienstleistungen - Erbringung von Freiberuflichen, Wissenschaftlichen und Technischen Dienstleistungen
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 50 million
Gesamtkosten (voraussichtlicher Betrag)
EUR 116 million
The project concerns research, development and innovation (RDI) activities within the Promoter's research centre in France. The project's compliance with all applicable national and EU environmental legislation will be verified during the appraisal. Environmental studies or appropriate assessments will be carried out as applicable and mitigating and/or compensation measures applied as necessary.
The Promoter has been assessed by the EIB as being a private company not subject to EU rules on public procurement or concessions. However, if after the project appraisal, the EIB were to conclude that the Promoter is after all subject to the EU public procurement legislation Directive 2014/24/EU, then the Bank would require that the Promoter ensure that contracts for the implementation of the project will be tendered in accordance with the relevant applicable EU procurement legislation Directive 2014/24/EU, where applicable, as well as Directive 89/665/EEC as interpreted by the Court of Justice of the European Union, with the publication of tender notices in the Official Journal of the European Union, as and where required.
Unterzeichnet - 2/06/2021
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).